GLP-1 Weight Loss for Women: Results, Hormones, and What to Expect

GLP-1 Weight Loss Results in Women

Large GLP-1 trials enroll roughly 65–70% women, so the headline results closely reflect female outcomes. In STEP 1:

• Overall average: 14.9% body weight loss
• Women specifically: Slightly higher average weight loss than the overall mean

In SURMOUNT-1 (tirzepatide), women also showed strong response at all doses.

Body composition differences between men and women (higher percentage body fat in women at similar BMI) mean that women and men may lose weight from different distributions, but the percentage outcomes are comparable.

Effects on Menstrual Cycles

Many women on GLP-1 medications report changes in their menstrual cycle. This is not directly caused by the medication — it's a consequence of rapid weight loss:

Weight loss-related effects:

• Irregular periods are common with rapid weight loss of any cause
• Hormonal shifts (estrogen stored in adipose tissue is released during fat loss)
• Some women experience missed periods, shorter cycles, or heavier bleeding temporarily

When to be concerned: If cycles are absent for 3+ months or bleeding is unusually heavy, consult your provider. Rarely, this warrants evaluation for other causes.

Most menstrual changes normalize once weight stabilizes.

GLP-1 and PCOS

Polycystic ovary syndrome (PCOS) is characterized by insulin resistance, androgen excess, and ovulatory dysfunction — often associated with obesity. GLP-1 medications are particularly beneficial for PCOS patients:

Documented benefits:

• Significant weight loss in women with PCOS
• Improved insulin sensitivity (central to PCOS pathophysiology)
• Restoration of ovulation in some previously anovulatory women
• Reduction in androgen levels alongside weight loss
• Improved hormonal profiles (SHBG, LH/FSH ratio)

Important implication: Restored ovulation means improved fertility. Women with PCOS who were previously not ovulating regularly may become fertile during GLP-1 treatment. Contraception should be addressed if pregnancy is not desired.

Contraception Considerations

Oral Contraceptive Efficacy

GLP-1 medications slow gastric emptying. This can affect the absorption of oral contraceptive pills — slower gastric transit may alter pill absorption timing, potentially reducing efficacy in some cases.

FDA labeling note: The prescribing information for semaglutide and tirzepatide recommends non-oral contraception or a barrier method as a backup during dose escalation.

Practical guidance:

• Discuss contraception method with your provider before starting GLP-1
• If you use oral contraceptives, consider an additional barrier method during the escalation phase (first ~5 months)
• Long-acting reversible contraceptives (IUD, implant) are unaffected by GLP-1 and are an excellent option

Pregnancy

GLP-1 medications are not recommended during pregnancy. Stop GLP-1 at least 2 months before planned conception (given semaglutide's long half-life). Tirzepatide should also be stopped well before attempting conception.

If you become pregnant while on GLP-1, stop the medication and contact your OB.

GLP-1 and Menopause

Weight gain during perimenopause and menopause is driven by hormonal shifts (declining estrogen) and metabolic changes. GLP-1 medications address the metabolic aspects effectively:

Benefits in menopausal women:

• GLP-1 produces comparable weight loss regardless of menopausal status
• Improvements in insulin sensitivity benefit postmenopausal metabolic risk
• Cardiovascular risk reduction (relevant given increased CVD risk post-menopause)
• Possible improvement in menopausal symptoms associated with obesity (hot flash severity correlates with BMI)

Interaction with hormone replacement therapy (HRT): No clinically significant interaction. Women on HRT can use GLP-1 medications without concern about drug-drug interaction.

Body Composition for Women on GLP-1

Like male patients, women on GLP-1 lose a mix of fat and lean mass. The lean mass loss concern is real for women, particularly given the accelerated muscle loss that occurs after menopause.

Strategies for women to optimize body composition:

• Resistance training 2–3 times per week (particularly important for postmenopausal women)
• Protein intake of 1–1.2g per kg body weight
• Consider working with a registered dietitian during treatment

Side Effects in Women

Side effect profiles are similar between men and women. Hair thinning — associated with rapid caloric restriction and weight loss rather than the medication directly — may be more distressing for women and is worth discussing with your provider. It's typically temporary (telogen effluvium) and resolves as weight stabilizes.

Bottom Line

GLP-1 medications produce excellent weight loss results in women, with outcomes at or above the overall trial averages. Women-specific considerations include menstrual cycle changes (normal, usually temporary), PCOS benefits (significant, including restored fertility), oral contraceptive interactions during escalation (use backup), and pregnancy avoidance (stop 2+ months before conception). For postmenopausal women, GLP-1 is effective and resistance training is especially important to protect muscle mass.

Sources

• Frías JP et al., "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes," NEJM, 2021
• Tay CT et al., "GLP-1 Receptor Agonists for Polycystic Ovary Syndrome," Lancet Regional Health, 2023
• Wilding JPH et al., "Once-Weekly Semaglutide in Adults with Overweight or Obesity," NEJM, 2021